Competition is on the horizon for costly narcolepsy treatments
pharmaphorum
DECEMBER 14, 2022
But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up. In 2020, the FDA-approved indication was expanded to include those patients who suffer from cataplexy.
Let's personalize your content